Encompass Health (NYSE:EHC) Updates FY24 Earnings Guidance

Encompass Health (NYSE:EHC) updated its FY24 earnings guidance on Monday. The company provided earnings per share guidance of $3.97-$4.22 for the period, compared to the consensus earnings per share estimate of $4.13. The company issued revenue guidance of $5.275-$5.350 billion, compared to the consensus revenue estimate of $5.30 billion.

Encompass Health Trading Down 3.2 %

Encompass Health stock traded down $2.99 during mid-day trading on Monday, hitting $89.72. The company’s stock had a trading volume of 1,278,542 shares, compared to its average volume of 647,243. The stock has a market cap of $9.03 billion, a PE ratio of 24.25, a P/E/G ratio of 1.45 and a beta of 0.89. Encompass Health has a one year low of $57.55 and a one year high of $94.38. The company has a 50 day moving average of $86.32 and a 200-day moving average of $81.11. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.76%. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. The ex-dividend date is Tuesday, October 1st. Encompass Health’s dividend payout ratio is presently 18.38%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Mizuho increased their price target on Encompass Health from $93.00 to $95.00 and gave the stock a buy rating in a report on Thursday, April 25th. Barclays lifted their price objective on shares of Encompass Health from $108.00 to $113.00 and gave the company an overweight rating in a research note on Wednesday, July 10th. Truist Financial increased their target price on Encompass Health from $95.00 to $100.00 and gave the stock a buy rating in a research note on Monday, July 15th. Leerink Partnrs raised shares of Encompass Health to a strong-buy rating in a research note on Wednesday, July 10th. Finally, Raymond James restated a strong-buy rating and set a $95.00 price objective (up previously from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Buy and an average price target of $98.86.

Insiders Place Their Bets

In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of Encompass Health stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the sale, the insider now owns 18,594 shares in the company, valued at approximately $1,580,861.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.10% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.